Clinical Trial

MRI Assessment of Pancreatic Fat Changes and Islet Function Recovery After Bariatric Surgery in Obese Patients

Study acronym: PANFAT-BS
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 12, 2026 (before its estimated April 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study evaluates changes in pancreatic fat and recovery of pancreatic function in obese patients undergoing laparoscopic sleeve gastrectomy (LSG), a weight-loss surgery. Obesity can cause fat to accumulate in the pancreas, which may impair insulin production and lead to type 2 diabetes. This study uses magnetic resonance imaging (MRI) to measure pancreatic fat before and after surgery to understand how weight loss affects pancreatic function. About 50 obese patients (BMI \> 32 kg/m²) aged 16-60 years who are scheduled for LSG will be enrolled. Participants will undergo MRI scans of the pancreas and blood tests before surgery and at 1, 3, and 6 months after surgery. The MRI uses a safe, non-invasive technique called Dixon imaging to measure fat content in different parts of the pancreas (head, body, and tail). Blood tests will measure fasting glucose, insulin, C-peptide, and HbA1c to assess pancreatic function. The study aims to determine whether reduction in pancreatic fat after weight-loss surgery is associated with improved insulin secretion and reduced insulin resistance. This information may help doctors better understand how bariatric surgery improves metabolic health and guide postoperative patient management. Participation involves no additional risk beyond routine clinical care. All MRI scans and blood tests are part of standard postoperative monitoring for bariatric surgery patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-06.
Trial Details
NCT Number NCT07464223
Lead Sponsor yu li,MD
Conditions Obesity & Overweight, Type 2 Diabetes Mellitus (T2DM), Pancreatic Steatosis, Insulin Resistance
Enrollment 50 participants
Start Date 2024-09-01
Primary Completion 2026-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-12